Meidan V M, Touitou E
Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University, Jerusalem, Israel.
Drugs. 2001;61(1):53-69. doi: 10.2165/00003495-200161010-00006.
Androgenetic alopecia and alopecia areata are common disorders of the hair follicle which may heavily influence self esteem and self image. Androgenetic alopecia is caused by the heightened sensitivity of scalp follicles to dihydro- testosterone whereas alopecia areata is induced by an autoimmune reaction. Current drug treatment approaches include the use of regrowth stimulators such as topical minoxidil and oral finasteride for androgenetic alopecia, as well as topical minoxidil, dithranol (anthralin), corticosteroids, contact sensitisers, and psoralen plus ultraviolet A irradiation (PUVA) therapy for alopecia areata. Combination regimens are also proposed. However, extreme cases of either type of alopecia do not generally respond well to these existing treatments. For this reason, new therapeutic strategies are directed towards both improving the targeting of existing agents, as well as the development of novel hypertrichotic modalities.
雄激素性脱发和斑秃是常见的毛囊疾病,可能会严重影响自尊和自我形象。雄激素性脱发是由头皮毛囊对二氢睾酮的敏感性增加引起的,而斑秃是由自身免疫反应诱发的。目前的药物治疗方法包括使用生发刺激剂,如外用米诺地尔和口服非那雄胺治疗雄激素性脱发,以及外用米诺地尔、地蒽酚(蒽林)、皮质类固醇、接触致敏剂和补骨脂素加紫外线A照射(PUVA)疗法治疗斑秃。也有人提出联合治疗方案。然而,这两种类型脱发的极端病例通常对这些现有治疗反应不佳。因此,新的治疗策略旨在改善现有药物的靶向性,以及开发新的促进毛发生长的方法。